Results 11 to 20 of about 2,835,752 (355)

Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury [PDF]

Archives of Toxicology, 2018
The transcription factor NRF2, governed by its repressor KEAP1, protects cells against oxidative stress. There is interest in modelling the NRF2 response to improve the prediction of clinical toxicities such as drug-induced liver injury (DILI). However, very little is known about the makeup of the NRF2 transcriptional network and its response to ...
Ian M. Copple, Wouter den Hollander, Giulia Callegaro, Fiona Mutter, James L. Maggs, Amy Schofield, Lucille Rainbow, Yongxiang Fang, Jeffrey J. Sutherland, Ewa Ellis, Magnus Ingelman‐Sundberg, Stephen Fenwick, Christopher E. Goldring, Bob van de Water, James Stevens, B. Kevin Park   +15 more
semanticscholar   +6 more sources

Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug‐induced liver injury [PDF]

Liver International, 2013
Background & aims: Several pharmaceutical compounds have been shown to exert inhibitory effects on the bile salt export pump (BSEP) encoded by the ABCB11 gene.
Eugenia Ulzurrun, Camilla Stephens, Esperanza Crespo, Francisco Ruiz‐Cabello, Julia Ruiz‐Nuñez, Pablo Sáenz-López, Inmaculada Moreno‐Herrera, Mercedes Robles‐Díaz, Hacibe Hallal, J.M. Moreno Planas, María R. Cabello, M. Isabel Lucena, Raúl J. Andrade   +12 more
core   +8 more sources

Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury

Chemical Research in Toxicology, 2019
Idiosyncratic drug-induced liver injury (iDILI), which is rare and often recognized only late in drug development, poses a major public health concern and impediment to drug development due to its high rate of morbidity and mortality. The mechanisms of DILI are not completely understood; both non-immune- and immune-mediated mechanisms have been ...
Serat-E Ali, J. Waddington, B. Kevin Park, Xiaoli Meng   +3 more
semanticscholar   +5 more sources

Editorial of Special Column on Drug- and Chemical-Induced Liver Injury

Acta Pharmaceutica Sinica B, 2021
James Luyendyk, Dafna Groeneveld
doaj   +4 more sources

Editor Profiles: Guest Editors of Special Column on Drug- and Chemical-Induced Liver Injury

Acta Pharmaceutica Sinica B, 2021
doaj   +4 more sources

MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury [PDF]

Journal of Clinical Medicine, 2015
Drug-induced liver injury (DILI) is major problem for both the drug industry and for clinicians. There are two basic categories of DILI: intrinsic and idiosyncratic. The former is the chief cause of acute liver failure in several developed countries, while the latter is the most common reason for post-marketing drug withdrawal and a major reason for ...
Mitchell R. McGill, Hartmut Jaeschke
openalex   +5 more sources

Treatment with gefitinib after erlotinib-induced liver injury: a case report [PDF]

Journal of Medical Case Reports, 2011
Introduction Gefitinib and erlotinib have minor differences in their chemical structures, and thus it remains unclear whether the hepatotoxicity induced by one compound is affected by the other. The case of a patient who developed erlotinib-induced liver
Nakatomi Katsumi, Nakamura Yoichi, Tetsuya Iida, Kohno Shigeru   +3 more
doaj   +3 more sources

Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury [PDF]

Toxicological Sciences, 2020
Abstract Drug-induced liver injury is a major reason for drug candidate attrition from development, denied commercialization, market withdrawal, and restricted prescribing of pharmaceuticals. The metabolic bioactivation of drugs to chemically reactive metabolites (CRMs) contribute to liver-associated adverse drug reactions in humans that
James J Monroe, Keith Q. Tanis, Alexei A. Podtelezhnikov, Truyen Nguyen, Sam V. Machotka, Donna Lynch, Raymond Evers, Jairam Palamanda, Randy R. Miller, Todd R. Pippert, Tamara D. Cabalu, Timothy E. Johnson, Amy G. Aslamkhan, Wen Kang, Alex M. Tamburino, Kaushik Mitra, Nancy Agrawal, Frank D. Sistare   +17 more
openalex   +4 more sources

Drug-induced liver injury due to tofacitinib: a case report

Journal of Medical Case Reports, 2023
Background Drug-induced liver injury is an acute or chronic liver damage in response to drugs, herbals, and any chemical compound. Case presentation In the present work, liver failure following the use of tofacitinib was reported.
Masoud Mardani, Jafar Mohammadshahi, Sara abolghasemi, Roghayeh Teimourpour   +3 more
doaj   +2 more sources

Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs

PLOS ONE, 2021
Drug-induced liver injury (DILI) is one of major causes of discontinuing drug development and withdrawing drugs from the market. In this study, we investigated chemical properties associated with DILI using in silico methods, to identify a physicochemical property useful for DILI screening at the early stages of drug development.
Yuki Shimizu, Takamitsu Sasaki, Jun‐ichi Takeshita, Michiko WATANABE, Ryota Shizu, Takuomi Hosaka, Kouichi Yoshinari   +6 more
openalex   +6 more sources